Literature DB >> 27829509

Plasma levels of Th17-related cytokines and complement C3 correlated with aggressive behavior in patients with schizophrenia.

Haozhe Li1, Qinting Zhang2, Ningning Li3, Fan Wang3, Hui Xiang3, Zongfeng Zhang3, Yousong Su3, Yueqi Huang3, Shengyu Zhang4, Guoqing Zhao3, Rubai Zhou3, Ling Mao5, Zhiguang Lin6, Weixiong Cai4, Yiru Fang3, Bin Xie6, Min Zhao6, Wu Hong7.   

Abstract

Increasing evidence indicates that immune inflammatory processes, especially autoimmune reaction, should be considered in the pathophysiology of schizophrenia and aggressive behavior. The present study aimed to explore the correlation between immune factors (C3 and Th17-related cytokines) and aggressive behavior in schizophrenia patients. Forty schizophrenia patients and forty age- and gender-matched healthy controls participated in the study. Blood samples were assessed by ELISA upon enrollment. Positive and negative syndrome scale (PANSS) and modified overt aggression scale (MOAS) were used to estimate the severity and aggressive symptoms of schizophrenia patients. Plasma levels of IL-17, IL-23, and TGF-β1 in schizophrenia patients were significantly higher than those in healthy controls [(37.63±17.82) vs. (29.34±10.38)pg/ml, p=0.02; (101.40±135.26) vs. (13.09±5.94) pg/ml, p=0.01; (2864.57±2163.61) vs. (1839.69±1797.73)pg/ml, p=0.04], whereas C3 levels were significantly lower in schizophrenia patients [( 120,479.67± 65,612.50) vs. ( 208,060.21± 217,008.21)ng/ml, p=0.02]. IL-17, IL-23, and TGF-β1 levels were positively related to total scores of MOAS (p=0.02, p=0.02 and p=0.03, respectively) and PANSS (p=0.04, p=0.04 and p=0.02, respectively), whereas C3 levels were negatively related to total PANSS scores (p=0.03). IL-17 and IL-23 levels were positively correlated with PANSS excited component scores (p=0.04 and p=0.01, respectively). Our findings suggested that the Th17-related cytokine levels were positively related to the severity of schizophrenia and aggressive behavior, whereas C3 levels were negatively related to the severity of schizophrenia. This study demonstrated that elevated levels of Th17-related cytokines and decreased levels of C3 could be potential biomarkers for schizophrenia and aggressive behavior.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Aggressive behavior; Autoimmunity; Complement component 3; Inflammatory cytokines; Schizophrenia

Mesh:

Substances:

Year:  2016        PMID: 27829509     DOI: 10.1016/j.psychres.2016.10.061

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  19 in total

1.  IL-17A Promotes Granulocyte Infiltration, Myelin Loss, Microglia Activation, and Behavioral Deficits During Cuprizone-Induced Demyelination.

Authors:  Julian Zimmermann; Michael Emrich; Marius Krauthausen; Simon Saxe; Louisa Nitsch; Michael T Heneka; Iain L Campbell; Marcus Müller
Journal:  Mol Neurobiol       Date:  2017-01-13       Impact factor: 5.590

Review 2.  Chorioamnionitis, IL-17A, and fetal origins of neurologic disease.

Authors:  Shelley M Lawrence; James L Wynn
Journal:  Am J Reprod Immunol       Date:  2017-12-22       Impact factor: 3.886

Review 3.  The complement system in schizophrenia: where are we now and what's next?

Authors:  Julia J Woo; Jennie G Pouget; Clement C Zai; James L Kennedy
Journal:  Mol Psychiatry       Date:  2019-08-22       Impact factor: 15.992

4.  The impact of the histone deacetylase inhibitor sodium butyrate on microglial polarization after oxygen and glucose deprivation.

Authors:  Karolina Ziabska; Justyna Gargas; Joanna Sypecka; Malgorzata Ziemka-Nalecz
Journal:  Pharmacol Rep       Date:  2022-07-07       Impact factor: 3.919

5.  Haptoglobin in ultra-high risk of psychosis - Findings from the longitudinal youth at risk study (LYRIKS).

Authors:  Jie Yin Yee; Si Qing Chow; Keane Lim; Wilson Goh; Judy Sng; Tih-Shin Lee; Jimmy Lee
Journal:  Brain Behav Immun Health       Date:  2022-06-12

6.  High Mobility Group Protein 1 and Dickkopf-Related Protein 1 in Schizophrenia and Treatment-Resistant Schizophrenia: Associations With Interleukin-6, Symptom Domains, and Neurocognitive Impairments.

Authors:  Arafat Hussein Al-Dujaili; Rana Fadhil Mousa; Hussein Kadhem Al-Hakeim; Michael Maes
Journal:  Schizophr Bull       Date:  2021-03-16       Impact factor: 9.306

Review 7.  Aberrant Complement System Activation in Neurological Disorders.

Authors:  Karolina Ziabska; Malgorzata Ziemka-Nalecz; Paulina Pawelec; Joanna Sypecka; Teresa Zalewska
Journal:  Int J Mol Sci       Date:  2021-04-28       Impact factor: 5.923

8.  TGF-β1 is associated with deficits in cognition and cerebral cortical thickness in first-episode schizophrenia.

Authors:  Shujuan Pan; Yanfang Zhou; Ling Yan; Fangling Xuan; Jinghui Tong; Yanli Li; Junchao Huang; Wei Feng; Song Chen; Yimin Cui; Fude Yang; Shuping Tan; Zhiren Wang; Baopeng Tian; L Elliot Hong; Yun-Long Tan; Li Tian
Journal:  J Psychiatry Neurosci       Date:  2022-03-17       Impact factor: 5.699

9.  Evaluation of plasma cytokines in patients with cocaine use disorders in abstinence identifies transforming growth factor alpha (TGFα) as a potential biomarker of consumption and dual diagnosis.

Authors:  Rosa Maza-Quiroga; Nuria García-Marchena; Pablo Romero-Sanchiz; Pedro Araos; Vicente Barrios; María Pedraz; Antonia Serrano; Raquel Nogueira-Arjona; Juan Jesus Ruiz; Maribel Soria; Rafael Campos; Julie Ann Chowen; Jesus Argente; Marta Torrens; Meritxell López-Gallardo; Eva María Marco; Fernando Rodríguez de Fonseca; Francisco Javier Pavón
Journal:  PeerJ       Date:  2017-10-12       Impact factor: 2.984

10.  Relationship of Brain-Derived Neurotrophic Factor with Interleukin-23, Testosterone and Disease Severity in Schizophrenia.

Authors:  Priya Allimuthu; Hanumanthappa Nandeesha; Raghavi Chinniyappan; Balaji Bhardwaz; Jesudas Blessed Raj
Journal:  Indian J Clin Biochem       Date:  2020-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.